Question to the Department for International Development:

To ask Her Majesty's Government what plans they have to extend their engagement with the Advanced Market Commitment beyond the pilot for pneumococcal vaccine, run via Gavi, the Vaccine Alliance.

The Advance Market Commitment (AMC) for Pneumococcal Vaccines is a dynamic financing instrument of Gavi, the Vaccine Alliance. Its objective is to reduce deaths from severe pneumonia by reducing the cost of the pneumococcal vaccine. The AMC does this by incentivising vaccine manufacturers and generating greater competition by encouraging additional manufacturers to the market. So far, 114 million children have been vaccinated with AMC-supported pneumococcal vaccines, saving 762,000 lives.

DFID has committed $485 million to AMC from 2010 until 2020. The AMC has consistently delivered and performs very strongly. It scored an A+ in its last Annual Review. The current end date is scheduled for December 2020. DFID are currently reviewing vaccine demand projections and in discussions with other stakeholders whether an extension is required in order to attract new manufacturers and generate wider benefits. This review is in line with our approach to maximise effectiveness and ensure good value for money.